Genotropin (Recombinant Human Growth Hormone)
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allogeneic Stem Cell Transplantation
Conditions
Allogeneic Stem Cell Transplantation
Trial Timeline
Sep 1, 2008 → Dec 1, 2013
NCT ID
NCT00737113About Genotropin (Recombinant Human Growth Hormone)
Genotropin (Recombinant Human Growth Hormone) is a phase 1 stage product being developed by Pfizer for Allogeneic Stem Cell Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00737113. Target conditions include Allogeneic Stem Cell Transplantation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00737113 | Phase 1 | Terminated |
Competing Products
9 competing products in Allogeneic Stem Cell Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar | Pfizer | Phase 3 | 76 |
| Inotuzumab Ozogamicin + Vincristine Sulfate Liposome | Pfizer | Phase 1/2 | 40 |
| immunosuppression | Pfizer | Phase 2 | 51 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 18 |
| Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo | Seres Therapeutics | Phase 1 | 25 |